*A total of 196 Asian patients were enrolled, including 103 patients in the desumumab group and 93 patients in the zoledronic acid group<br>Compared with zoledronic acid PFS, agavix has a nearly 11 month longer disease progression risk and 18% lower risk of disease progression<br>PFS curve evaluated by Kaplan Meier<br>PFS(%)<br>Deshumab<br>Zoledronic acid<br>Number of patients at risk<br>Deshumab<br>Zoledronic acid<br>Time after randomization (months)<br>Deshumab<br>Zoledronic acid<br>Median PFS,<br>Month (95% CI)<br>
正在翻译中..